Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk Model for Prostate Cancer Using Environmental and Genetic Factors in the Spanish Multi-Case- Control (MCC) Study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Fernández-Navarro, Pablo|||0000-0001-9427-2581
  • Palazuelos, Camilo
  • Morros, Rosa|||0000-0001-6752-8748
  • Aragonés, Nuria
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Jiménez Monleón, Jose J.
  • Ruiz Cerdá, José Luis
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Ruiz-Dominguez, José Manuel
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Pollán, Marina|||0000-0002-4328-1565
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Llorca, Javier|||0000-0001-8569-861X
Prostate cancer (PCa) is the second most common cancer among men worldwide. Its etiology remains largely unknown compared to other common cancers. We have developed a risk stratification model combining environmental factors with family history and genetic susceptibility. 818 PCa cases and 1,006 healthy controls were compared. Subjects were interviewed on major lifestyle factors and family history. Fifty-six PCa susceptibility SNPs were genotyped. Risk models based on logistic regression were developed to combine environmental factors, family history and a genetic risk score. In the whole model, compared with subjects with low risk (reference category, decile 1), those carrying an intermediate risk (decile 5) had a 265% increase in PCa risk (OR = 3.65, 95% CI 2.26 to 5.91). The genetic risk score had an area under the ROC curve (AUROC) of 0.66 (95% CI 0.63 to 0.68). When adding the environmental score and family history to the genetic risk score, the AUROC increased by 0.05, reaching 0.71 (95% CI 0.69 to 0.74). Genetic susceptibility has a stronger risk value of the prediction that modifiable risk factors. While the added value of each SNP is small, the combination of 56 SNPs adds to the predictive ability of the risk model.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Alkylphenolic compounds and risk of breast and prostate cancer in the MCC-Spain study

  • Peremiquel-Trillas, Paula
  • Benavente, Yolanda|||0000-0003-1422-4614
  • Martín-Bustamante, Mayte
  • Casabonne, Delphine
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Oliete-Canela, Anna
  • Diéguez-Rodríguez, Marta
  • Tusquets, Ignasi
  • Amiano, Pilar
  • Mengual, Lourdes
  • Ardanaz, Eva
  • Capelo, Rocío
  • Molina de la Torre, Antonio José
  • Salas Trejo, Dolores
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Lope, Virginia
  • Jimenez-Moleon, José J.
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Azpiri, Mikel
  • Muñoz, Montse
  • Guevara, Marcela|||0000-0001-9242-6364
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Molina-Barceló, Ana|||0000-0001-5113-6475
  • Aragonés, Nuria
  • Pollán, Marina|||0000-0002-4328-1565
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Alguacil, Juan|||0000-0003-2703-9725
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • De Sanjose, Silvia|||0000-0002-5909-676X
  • Costas, Laura
Background: Alkylphenolic compounds are chemicals with endocrine disrupting properties that have been widely used in industry with important changes in their usage over time. Few epidemiologic studies have evaluated the effect of alkylphenolic compounds on human health. Objectives: We investigated whether occupational exposure to alkylphenolic compounds is associated with breast and prostate cancer. Methods: We carried out a population-based case-control study including 1513 incident cases of breast cancer, 1095 of prostate cancer, and 3055 controls, frequency matched by sex, age and region. Occupational exposure to alkylphenolic compounds was estimated using a recently developed job-exposure matrix, which considered different scenarios of exposure and different subtypes of alkylphenolic compounds. Results: History of occupational exposure to alkylphenolic compounds was modestly associated with breast cancer (OR = 1.23; 95% CI = 1.01-1.48). Within the different scenarios, the occupational use of domestic tensioactives was positively associated with breast cancer (OR = 1.28; 95% CI = 1.02-1.60), while occupational exposure in other scenarios showed mostly a suggestion of a similar positive associations. Exposure to nonylphenol ethoxylates was positively associated with breast cancer (OR = 1.21; 95% CI = 1.00-1.47), while exposure to other compounds was uncommon. In general, we did not observe associations between alkylphenolic compounds and prostate cancer, except for a positive association among men occupationally exposed to cosmetic, hair and personal hygiene products. Conclusions: Our findings suggest a modest association between breast cancer risk and occupational exposure to alkylphenolic compounds, and no associations between these compounds and prostate cancer risk. These findings warrant further corroboration in other studies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tumour characteristics and survivorship in a cohort of breast cancer, the MCC-Spain study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Palazuelos-Calderón, Camilo
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Amiano, Pilar
  • Guevara, Marcela|||0000-0001-9242-6364
  • Molina de la Torre, Antonio José
  • Domingo, Laia|||0000-0003-4420-0891
  • Fernández-Ortiz, María|||0000-0003-0017-875X
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Alguacil, Juan|||0000-0003-2703-9725
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Ibáñez, Josefa
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Diaz-Santos, Marian
  • Alonso, M. Henar
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • García Palomo, Andrés|||0000-0002-9159-9025
  • Ardanaz, Eva
  • Molinuevo, Amaia
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The objective of this study is to analyse the relative survival with breast cancer in women diagnosed after new treatments were generalised and to ascertain the current effect that tumour characteristics such as grade, stage or subtype have on survival as well as the new AJCC-pathological prognostic score. The breast cancer MCC-Spain follow-up study is a prospective cohort study of 1685 incident breast cancer cases. Women between 20 and 85 years old were recruited between the years 2008 and 2013 in 18 hospitals located in 10 Spanish provinces and they have been followed until 2017/2018. Relative survival was estimated after 3, 5 and 8 years of follow-up using Ederer II method. In addition, Weibull regression adjusted by age, hospital, grade and stage was used to investigate prognosis factors. Among components of TNM staging system, tumour size greater than 50 mm (i.e. T3 or T4) more than doubled the risk of dying, while N3 nodal involvement and presence of metastasis had a huge effect on mortality. The AJCC pathological prognostic score strongly correlated with survival; thus, hazard ratios increased as the score rose, being 2.31, 4.00, 4.94, 7.92, 2.26, 14.9 and 58.9 for scores IB, IIA, IIB, IIIA, IIIB, IIIC and IV, respectively. Both TNM staging and histological/molecular biomarkers are associated with overall survival in Spanish women with breast cancer; when both are combined in the AJCC pathological prognosis score, the prognostic value improved with risk indices that increased rapidly as the pathological prognosis score increased The online version of this article (10.1007/s10549-020-05600-x) contains supplementary material, which is available to authorised users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effect of mistimed eating patterns on breast and prostate cancer risk (MCC-Spain Study)

  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Espinosa, Ana|||0000-0001-7399-3267
  • Castelló, Adela|||0000-0002-1308-9927
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Guevara, Marcela|||0000-0001-9242-6364
  • Martín, Vicente|||0000-0003-0552-2804
  • Amiano, Pilar
  • Alguacil, Juan|||0000-0003-2703-9725
  • Peiro, Rosana
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Costas, Laura
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Jimenez, Jose Juan
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Llorca, Javier|||0000-0001-8569-861X
  • Moreno-Iribas, Conchi|||0000-0001-6537-0131
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Oribe, Madalen
  • Aragonés, Nuria
  • Papantoniou, Kyriaki|||0000-0002-0340-9659
  • Pollán, Marina|||0000-0002-4328-1565
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Romaguera, Dora|||0000-0002-5762-8558
Modern life involves mistimed sleeping and eating patterns that in experimental studies are associated with adverse health effects. We assessed whether timing of meals is associated with breast and prostate cancer risk taking into account lifestyle and chronotype, a characteristic correlating with preference for morning or evening activity. We conducted a population-based case-control study in Spain, 2008-2013. In this analysis we included 621 cases of prostate and 1,205 of breast cancer and 872 male and 1,321 female population controls who had never worked night shift. Subjects were interviewed on timing of meals, sleep and chronotype and completed a Food Frequency Questionaire. Adherence to the World Cancer Research Fund/American Institute of Cancer Research recommendations for cancer prevention was examined. Compared with subjects sleeping immediately after supper, those sleeping two or more hours after supper had a 20% reduction in cancer risk for breast and prostate cancer combined (adjusted Odds Ratio [OR] = 0.80, 95%CI 0.67-0.96) and in each cancer individually (prostate cancer OR = 0.74, 0.55-0.99; breast cancer OR = 0.84, 0.67-1.06). A similar protection was observed in subjects having supper before 9 pm compared with supper after 10 pm. The effect of longer supper-sleep interval was more pronounced among subjects adhering to cancer prevention recommendations (OR both cancers= 0.65, 0.44-0.97) and in morning types (OR both cancers = 0.66, 0.49-0.90). Adherence to diurnal eating patterns and specifically a long interval between last meal and sleep are associated with a lower cancer risk, stressing the importance of evaluating timing in studies on diet and cancer. What's new? Evidence shows that long-term disruption of endogenous circadian rhythms may be associated with cancer. The effects of mistimed sleeping and eating patterns that come with modern life are however less clear. This large Spanish population-based study examined whether meal timing and sleep patterns are associated with the two most common nightshift-related cancers. Adherence to a more diurnal eating pattern, and specifically an early supper and a long interval between last meal and sleep were associated with a lower breast and prostate cancer risk, stressing the importance of evaluating circadian rhythms in diet and cancer studies and revisiting recommendations for prevention.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dietary Constituents, Relationship with Breast Cancer Prognostic (MCC-SPAIN Follow-Up)

  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Gutiérrez-Ruiz, Nuria
  • Aragonés, Nuria
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Guevara, Marcela|||0000-0001-9242-6364
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Obón-Santacana, Mireia|||0000-0003-4646-3513
  • Fernández-Tardon, Guillermo|||0000-0002-7680-158X
  • Molina-Barceló, Ana|||0000-0001-5113-6475
  • Alguacil, Juan|||0000-0003-2703-9725
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Rodríguez-Cundín, Paz
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Canseco Fernandez, Rosario
  • Castilla, Jesus|||0000-0002-6396-7265
  • Molinuevo, Amaia
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The aim of this study was to characterize the relationship between the intake of the major nutrients and prognosis in breast cancer. A cohort based on 1350 women with invasive (stage I-IV) breast cancer (BC) was followed up. Information about their dietary habits before diagnosis was collected using a semi-quantitative Food Frequency Questionnaire. Participants without FFQ or with implausible energy intake were excluded. The total amount consumed of each nutrient (Kcal/day) was divided into tertiles, considering as "high intakes" those above third tertile. The main effect studied was overall survival. Cox regression was used to assess the association between death and nutrient intake. During a median follow-up of 6.5 years, 171 deaths were observed. None of the nutrients analysed was associated with mortality in the whole sample. However, in normal-weight women (BMI 18.5-25 kg/m 2) a high intake of carbohydrates (≥809 Kcal/day), specifically monosaccharides (≥468 Kcal/day), worsened prognostic compared to lowest (≤352 Kcal/day). Hazard Ratios (HRs) for increasing tertiles of intake were HR:2.22 95% CI (1.04 to 4.72) and HR:2.59 95% CI (1.04 to 6.48), respectively (p trend = 0.04)). Conversely, high intakes of polyunsaturated fats (≥135 Kcal/day) improved global survival (HR: 0.39 95% CI (0.15 to 1.02) p -trend = 0.05) compared to the lowest (≤92.8 kcal/day). In addition, a protective effect was found substituting 100 kcal of carbohydrates with 100 kcal of fats in normal-weight women (HR: 0.76 95% CI (0.59 to 0.98)). Likewise, in premenopausal women a high intake of fats (≥811 Kcal/day) showed a protective effect (HR:0.20 95% CI (0.04 to 0.98) p trend = 0.06). Finally, in Estrogen Receptors (ER) negative tumors, we found a protective effect of high intake of animal proteins (≥238 Kcal/day, HR: 0.24 95% CI (0.06 to 0.98). According to our results, menopausal status, BMI and ER status could play a role in the relationship between diet and BC survival and must be taken into account when studying the influence of different nutrients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Validating a breast cancer score in Spanish women. The MCC-Spain study

  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Palazuelos, Camilo
  • Fernández-Navarro, Pablo|||0000-0001-9427-2581
  • Altzibar, Jone M.
  • González-Donquiles, Carmen
  • Ardanaz, Eva
  • Bustamante, Mariona|||0000-0003-0127-2860
  • Alonso Molero, Jessica|||0000-0002-1939-8798
  • Vidal, Carmen|||0000-0003-2768-2710
  • Bayo-Calero, Juan
  • Tardón, Adonina|||0000-0001-5150-1209
  • Salas, Dolores|||0000-0003-0064-1222
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Morros, Rosa|||0000-0001-6752-8748
  • Rodriguez-Cundin, Paz
  • Vinyals, Gemma Castaño
  • Ederra, María
  • Vilorio-Marqués, Laura
  • Amiano, Pilar
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
A breast-risk score, published in 2016, was developed in white-American women using 92 genetic variants (GRS92), modifiable and non-modifiable risk factors. With the aim of validating the score in the Spanish population, 1,732 breast cancer cases and 1,910 controls were studied. The GRS92, modifiable and non-modifiable risk factor scores were estimated via logistic regression. SNPs without available genotyping were simulated as in the aforementioned 2016 study. The full model score was obtained by combining GRS92, modifiable and non-modifiable risk factor scores. Score performances were tested via the area under the ROC curve (AUROC), net reclassification index (NRI) and integrated discrimination improvement (IDI). Compared with non-modifiable and modifiable factor scores, GRS92 had higher discrimination power (AUROC: 0.6195, 0.5885 and 0.5214, respectively). Adding the non-modifiable factor score to GRS92 improved patient classification by 23.6% (NRI = 0.236), while the modifiable factor score only improved it by 7.2%. The full model AUROC reached 0.6244. A simulation study showed the ability of the full model for identifying women at high risk for breast cancer. In conclusion, a model combining genetic and risk factors can be used for stratifying women by their breast cancer risk, which can be applied to individualizing genetic counseling and screening recommendations.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Use of Antihypertensive Medication and the Risk of Breast Cancer in a Case-Control Study in a Spanish Population, The MCC-Spain Study

  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Palazuelos, Camilo
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Lope, Virginia
  • Tusquets, Ignasi
  • Alonso, María Henar
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Amiano, Pilar
  • Molina de la Torre, Antonio José
  • Barricarte, Aurelio
  • Tardón, Adonina|||0000-0001-5150-1209
  • Camacho, Antonio
  • Peiro-Perez, Rosana
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Muñoz, Montse
  • Michelena-Echeveste, Maria Jesus
  • Ortega Valin, Luis
  • Guevara, Marcela|||0000-0001-9242-6364
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The evidence on the relationship between breast cancer and different types of antihypertensive drugs taken for at least 5 years is limited and inconsistent. Furthermore, the debate has recently been fueled again with new data reporting an increased risk of breast cancer among women with a long history of use of antihypertensive drugs compared with nonusers. In this case-control study, we report the antihypertensive drugs-breast cancer relationship in 1,736 breast cancer cases and 1,895 healthy controls; results are reported stratifying by the women's characteristics (i.e., menopausal status or body mass index category) tumor characteristics and length of use of antihypertensive drugs. The relationship among breast cancer and use of calcium channel blockers (CCB) for 5 or more years had odds ratio (OR) = 1.77 (95% CI, 0.99 to 3.17). Stratifying by BMI, the OR increased significantly in the group with BMI ≥ 25 (OR 2.54, 95% CI, 1.24 to 5.22). CCBs were even more strongly associated with more aggressive tumors, (OR for invasive tumors = 1.96, 95% CI = 1.09 to 3.53; OR for non ductal cancers = 3.97, 95% CI = 1.73 to 9.05; OR for Erbb2+ cancer = 2.97, 95% CI: 1.20 to 7.32). On the other hand, premenopausal women were the only group in which angiotensin II receptor blockers may be associated with breast cancer (OR = 4.27, 95% CI = 1.32 to 13.84) but this could not be identified with any type or stage. Use of angiotensin-converting-enzyme inhibitors, beta blockers and diuretics were not associated with risk. In this large population-based study we found that long term use of calcium channel blockers is associated with some subtypes of breast cancer (and with breast cancer in overweight women).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Use of non-steroidal anti-inflammatory drugs and risk of breast cancer, The Spanish Multi-Case-control (MCC) study

  • Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
  • Gomez-Acebo, Ines|||0000-0001-8793-8314
  • de Pedro, María
  • Pérez-Gómez, Beatriz|||0000-0002-4299-8214
  • Servitja, Sonia|||0000-0001-6988-4519
  • Morros, Rosa|||0000-0001-6752-8748
  • Amiano, Pilar
  • Fernández-Villa, Tania|||0000-0002-9049-3026
  • Barricarte, Aurelio
  • Tardón, Adonina|||0000-0001-5150-1209
  • Diaz-Santos, Marian
  • Peiro-Perez, Rosana
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
  • Lope, Virginia
  • Gracia-Lavedan, Esther
  • Alonso, M. Henar
  • Michelena-Echeveste, Maria Jesus
  • García Palomo, Andrés|||0000-0002-9159-9025
  • Guevara, Marcela|||0000-0001-9242-6364
  • Castaño-Vinyals, Gemma|||0000-0003-4468-1816
  • Aragonés, Nuria
  • Kogevinas, Manolis|||0000-0002-9605-0461
  • Pollán, Marina|||0000-0002-4328-1565
  • Llorca, Javier|||0000-0001-8569-861X
The relationship between non-steroidal anti-inflammatory drug (NSAID) consumption and breast cancer has been repeatedly studied, although the results remain controversial. Most case-control studies reported that NSAID consumption protected against breast cancer, while most cohort studies did not find this effect. Most studies have dealt with NSAIDs as a whole group or with specific drugs, such aspirin, ibuprofen, or others, but not with NSAID subgroups according to the Anatomical Therapeutic Chemical Classification System; moreover, scarce attention has been paid to their effect on different tumor categories (i.e.: ductal/non-ductal, stage at diagnosis or presence of hormonal receptors). In this case-control study, we report the NSAID - breast cancer relationship in 1736 breast cancer cases and 1895 healthy controls; results are reported stratifying by the women's characteristics (i.e.: menopausal status or body mass index category) and by tumor characteristics. In our study, NSAID use was associated with a 24 % reduction in breast cancer risk (Odds ratio [OR] = 0.76; 95 % Confidence Interval [CI]: 0.64-0.89), and similar results were found for acetic acid derivatives, propionic acid derivatives and COXIBs, but not for aspirin. Similar results were found in postmenopausal and premenopausal women. NSAID consumption also protected against hormone + or HER2+ cancers, but not against triple negative breast cancers. The COX-2 selectivity showed an inverse association with breast cancer (i.e. OR < 1), except in advanced clinical stage and triple negative cancers. Most NSAIDs, but not aspirin, showed an inverse association against breast cancer; this effect seems to be restricted to hormone + or HER2+ cancers. The online version of this article (doi:10.1186/s12885-016-2692-4) contains supplementary material, which is available to authorized users.